



08-12-05

Cofc

EXPRESS MAIL NO.: EV 475 141 475 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. Patent No.: 6,897,231 B2 (U.S. application no. 09/910,950, filed July 23, 2001)

Issued: May 24, 2005

Inventor(s): Bhagwat et al.

For: INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO

Attorney Docket No.: 10624-047-999
(CAM: 700755-999046)**REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 C.F.R. §1.322****Attention Certificate of Correction Branch**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**Certificate**
AUG 17 2005
of Correction

Sir:

Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050.

The errors were made by the United States Patent and Trademark Office ("USPTO") in connection with the above patent, wherein at:

claim 7, column 313, line 61, please replace " $-(OH_2)_a-$ " with $--(CH_2)_a--$;

claim 7, column 314, line 10, please replace " $-O(=O)R_8-$ " with $--C(=O)R_8--$;

and please delete claims 2, 3, 11, 12, 20 and 21.

Enclosed is a copy of a Second Supplemental Reply to Final Office Action Under 37 C.F.R. § 1.116 filed in the USPTO in connection with the above-identified patent application on June 9, 2004 evidencing the corrections in issued claim 7 (*i.e.*, claim 20 in the Second Supplemental Reply) as set forth above. Further enclosed is a copy (both sides) of a return-receipt postcard evidencing receipt of the Second Supplemental Reply to Final Office Action Under 37 C.F.R. § 1.116 by the USPTO on June 9, 2004.

Further enclosed is a copy of a Corrected Notice of Allowance and Fee(s) Due mailed by the USPTO on November 2, 2004 in connection with the above-identified application wherein claims 10, 11, 90, 91, 107 and 108 (which correspond to issued claims

AUG 17 2005

2, 3, 11, 12, 20 and 21) were canceled by an Examiner's amendment. Thus, the errors occurred on the part of the USPTO.

No fee is believed to be due in connection with this request since the errors were made by the USPTO. Should any fees be required, however, please charge such fees to Jones Day Deposit Account No. 50-3013. Please issue a certificate of correction as soon as possible.

Date: August 10, 2005

Respectfully submitted,
Anthony M. Insogna, Reg. No. 35,203
By: Michael D. Bruner Reg. No. 47,458
35,203
Anthony M. Insogna (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130



UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,897,231 B2
DATED : May 24, 2005
INVENTOR(S) : Bhagwat et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At claim 7, column 313, line 61, please replace " $-(\text{OH}_2)_a-$ " with -- $-(\text{CH}_2)_a-$ --;

At claim 7, column 314, line 10, please replace " $-\text{O}(=\text{O})\text{R}_8-$ " with -- $-\text{C}(=\text{O})\text{R}_8-$ --; and

Please delete claims 2, 3, 11, 12, 20 and 21.

MAILING ADDRESS OF SENDER:
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130

FORM PTO 1050

PATENT NO. 6,897,231 B2

No. of add'l. copies
@ 30¢ perpage

AUG 17 2005 ==>

NYJD: 1586548.1



UNITED STATES PATENT AND TRADEMARK OFFICE




20583

JONES DAY
222 EAST 41ST ST
NEW YORK, NY 10017

Issue + Publication
Fee Paid 9/16/04

11/02/2004



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

EXAMINER

STOCKTON, LAURA LYNNE

ART UNIT PAPER NUMBER

1626

DATE MAILED: 11/02/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,950	07/23/2001	Shripad S. Bhagwat	10624-047-999	3712

TITLE OF INVENTION: INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$685	\$0	\$685	11/09/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. NEITHER A NOTICE OF ALLOWANCE NOR A CORRECTED NOTICE OF ALLOWANCE IS A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND ANY PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THE THREE MONTH PERIOD BEGINNING ON THE MAILING DATE OF THE PREVIOUSLY-MAILED NOTICE OF ALLOWANCE AND ENDING ON THE DATE DUE SHOWN ON THIS FORM, OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. MAILING OF THIS CORRECTED NOTICE OF ALLOWANCE DOES NOT CHANGE THE DATE DUE OF THE ISSUE FEE (AND ANY REQUIRED PUBLICATION FEE). IF A REPLY (WITH PAYMENT OF THE ISSUE FEE AND ANY PUBLICATION FEE) WAS FILED IN RESPONSE TO THE PREVIOUSLY-MAILED NOTICE OF ALLOWANCE, THEN NO FURTHER REPLY IS REQUIRED FROM APPLICANT.

All communications regarding this application must include the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE, unless advised to the contrary.

AUG 17 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,950	07/23/2001	Shripad S. Bhagwat	10624-047-999	3712
20583	7590	11/02/2004	EXAMINER	
JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017			STOCKTON, LAURA LYNNE	
			ART UNIT	PAPER NUMBER
			1626	
DATE MAILED: 11/02/2004				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)


The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

AUG 17 2005



**Supplemental
Notice of Allowability**

Application No.

09/910,950

Examiner

Laura L. Stockton, Ph.D.

Applicant(s)

BHAGWAT ET AL.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the IDS filed June 18, 2003.
2. ☒ The allowed claim(s) is/are 6, 12, 18-20, 74, 85, 89, 92, 98-100, 104-106, 109 and 114-117, now renumbered claims 1-20, respectively.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date June 18, 2003
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material

5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),
Paper No./Mail Date 102004.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

LAURA L. STOCKTON, PH.D.
PRIMARY EXAMINER

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Michael J. Bruner on November 1, 2004.

The application has been amended as follows:

In the Claims:

Cancel claims 10, 11, 90, 91, 107 and 108.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.


AUG 17 2005

Application/Control Number: 09/910,950
Art Unit: 1626

Page 3

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Official fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.



Laura L. Stockton, Ph.D.

Patent Examiner

Art Unit 1626, Group 1620

Technology Center 1600

November 1, 2004

AUG 17 2005

Examiner-Initiated Interview Summary

Application No.

09/910,950

Applicant(s)

BHAGWAT ET AL.

Examiner

Laura L. Stockton, Ph.D.

Art Unit

1626

All Participants:

(1) Laura L. Stockton, Ph.D.

(2) Michael J. Bruner (Reg. No. 47,458).

Status of Application: 94

(3) Anthony M. Insogna (Reg. No. 35,203).

(4) _____.

Date of Interview: 20 October 2004

Time: 3:30pm

Type of Interview:

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

10, 11, 90, 91, 107 and 108

Prior art documents discussed:

US Pats. 6,531,491 and 6,534,524

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

AUG 17 2005

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner called Applicants' representative to discuss two US Patents which were listed on an unconsidered IDS filed June 18, 2003. The Examiner indicated that the US Patents raised a question of patentability for independent claims 10 and 11, and claims which depended from these claims. On October 21, 2004 @ 2:15am, Applicants' representative proposed a solution to circumvent the US Patents. However, on October 25, 2004 @ 10:41am, the Examiner indicated to Mr. Bruner that Applicants' specie (found in claims 107 and 108) would not be embraced by their perspective independent claims. On November 1, 2004 @ 10:43am, Mr. Bruner called the Examiner to give permission to cancel claims 10, 11, 90, 91, 107 and 108 without prejudice of filing a continuation on same.

11/1/04

AUG 17 2005

Express Mail No EV 475 140 515 US

First Class Mail ☐

Date Mailed June 9, 2004

Serial No. 09/910,950

Filed July 23, 2001

Inventor Bhagwat et al.


For, **INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS OF USE—RELATED THERETO**

- | | |
|--|--|
| <input type="checkbox"/> Affidavit/Declaration | <input type="checkbox"/> Fee Address Indication Form |
| <input type="checkbox"/> Response Amendment | <input type="checkbox"/> Fee Calculation |
| <input type="checkbox"/> Application pages | <input type="checkbox"/> Issue Fee Transmittal |
| <input type="checkbox"/> Claims | <input type="checkbox"/> Letter |
| <input type="checkbox"/> Drawing Sheets | <input type="checkbox"/> Oral Hearing Request/Confirm |
| <input type="checkbox"/> Appeal Notice of | <input type="checkbox"/> Petition to Extend Time (Two Months) |
| <input type="checkbox"/> Assignment | <input type="checkbox"/> Petition Under 37 C.F.R. |
| <input type="checkbox"/> Brief (in Triplicate) | <input type="checkbox"/> Power of Attorney |
| <input type="checkbox"/> Declaration & Power of Attorney | <input type="checkbox"/> Associate <input type="checkbox"/> w/Revocation |
| <input type="checkbox"/> Design Application | <input type="checkbox"/> Sequence Listing w/ Computer Readable |
| <input type="checkbox"/> Disclaimer | <input type="checkbox"/> and Paper Copy of Filing Receipt |
| <input type="checkbox"/> Disclosure Statement <input type="checkbox"/> Form PTO-1449 | <input type="checkbox"/> Small Entity Statement |
| <input type="checkbox"/> <input type="checkbox"/> w/refs <input type="checkbox"/> w/o refs | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Drawings Format | <input type="checkbox"/> Transmittal Letter |
| <input type="checkbox"/> Sheets <input type="checkbox"/> Figures | <input checked="" type="checkbox"/> Fee By Deposit Account 50-3013 |



Other: **SECOND SUPPLEMENTAL REPLY TO FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.116**

File no: 10624-047-999 (CAM # 700755-999046) Sender: Anthony M. Insogna/Michael J. Brimer (AMI/MJB)



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES

BUSINESS REPLY MAIL

FIRST-CLASS MAIL PERMIT NO. 1825 NEW YORK NY

POSTAGE WILL BE PAID BY ADDRESSEE

JONES DAY
222 E 41ST ST FL 4
NEW YORK NY 10164-3474



EXPRESS MAIL NO. EV 475 140 515 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat *et al.*

Confirmation No.: 3712

Application Serial No.: 09/910,950

Group Art Unit: 1626

Filed: July 23, 2001

Examiner: L. Stockton

For: INDAZOLE DERIVATIVES AS JNK
INHIBITORS AND COMPOSITIONS
AND METHODS OF USE RELATED
THERE TO

Attorney Docket No.: 10624-047-999
CAM: #700755-999046

**SECOND SUPPLEMENTAL REPLY TO
FINAL OFFICE ACTION UNDER 37 C.F.R. § 1.116**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Advisory Action mailed May 19, 2004 and in view of informal teleconferences on March 10, 2004 and March 12, 2004 with the Examiner, please enter the following amendments and consider the following remarks intended to place this application into form for allowance. The present Second Supplemental Reply is identical to the Supplemental Reply to Final Office Action Under 37 C.F.R. § 1.116 filed on April 27, 2004 in connection with the above-identified application, with the exception that claims 118 and 119, including status identifiers, are set forth in the listing of claims.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 27 of this paper.

2005 1 7 2005


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-5. (Canceled)

6. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is $-(CH_2)_bC \equiv C(CH_2)_c-$;

R₁ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R₃;

R₂ is -R₃, -R₄, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R₃ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

AUG 17 2005


R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3 , or R_4 is halogen or hydroxy;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

7-9. (Canceled)

10. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is $-(CH_2)_bC(=O)R_5$;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

11. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is $-(CH_2)_bC(=O)NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

12. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is $-(CH_2)_bNR_5C(=O)R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

AUG 17 2005


heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

13-17. (Canceled)

18. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is R_4 ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;


R_4 is 3-triazolyl, optionally substituted at its 5-position with:

- (a) a C_1 - C_4 straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
- (b) a 2-pyrrolidinyl group;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

19. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is R_4 ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is tetrazole;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

20. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

AUG 17 2005

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

R_2 is R_4 ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;


R_4 is imidazole;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

21-73. (Canceled)

74. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

-A-R₁ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR₈C(=O)R₉, -C(=O)NR₈R₉, and -O(CH₂)_bNR₈R₉;

R₂ is 3-triazolyl or 5-tetrazolyl;

a is 1, 2, 3, 4, 5 or 6;

b is 2 or 3;

c is at each occurrence 0, 1, 2, 3 or 4;


R₃ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -C(=O)R₈, -C(O)NR₈R₉, -C(=O)NR₈OR₉, -SO₂NR₈R₉, -NR₈SO₂R₉, -CN, -NO₂, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

R₅, R₆ and R₇ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R₅, R₆ and R₇ are optionally substituted with one to four substituents independently selected from R₃; and

R₈ and R₉ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R₈ and R₉ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R₈, R₉, and R₈ and R₉ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R₃.

75-84. (Canceled)

85. (Previously presented) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R₁ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R₃;

R₂ is R₄;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

R₃ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R₄ is 3-triazolyl, optionally substituted at its 5-position with:

(a) methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl;

R₅, R₆ and R₇ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R₅, R₆ and R₇ are optionally substituted with one to four substituents independently selected from R₃; and

MAR 17 2005

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

86-88. (Canceled)

89. (Previously presented) A composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.

90. (Previously presented) A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.

91. (Previously presented) A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier.

92. (Previously presented) A composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.

93-97. (Canceled)

98. (Previously presented) A composition comprising the compound of claim 18 and a pharmaceutically acceptable carrier.

99. (Previously presented) A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

100. (Previously presented) A composition comprising the compound of claim 20 and a pharmaceutically acceptable carrier.

101-103. (Canceled)

104. (Previously presented) A composition comprising the compound of claim 74 and a pharmaceutically acceptable carrier.

AUG 17 2005

105. ((Previously presented) A composition comprising the compound of claim 85 and a pharmaceutically acceptable carrier.

106. (Previously presented) A compound of claim 6, wherein the compound is:

3-(2-phenylethynyl)-1H-indazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.

107. (Previously presented) A compound of claim 10, wherein the compound is:

1-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl) piperidine-4-carboxylic acid;
3-(4-fluorophenyl)(1H-indazol-5-yl) pyrrolidinyl ketone;
3-(4-fluorophenyl)(1H-indazol-5-yl)piperazinyl ketone;
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethan-1-one; or a pharmaceutically acceptable salt thereof.

108. (Previously presented) A compound of claim 11, wherein the compound is:

3-(4-fluorophenyl)-1H-indazole-5-carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-benzamide;
N-(2-(dimethylamino)ethyl)3-(4-fluorophenyl) (1H-indazol-5-yl)carboxamide;
methyl 4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)benzoate;
4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)benzoic acid;
4-((3-(4-fluorophenyl)-1H-indazole-5-yl)carbonylamino)benzamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridyl)carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridyl)carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridyl)carboxamide;
tert-butyl 3-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)propanoate;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxyphenyl)carboxamide;
3-((3-(4-fluorophenyl)-1H-Indazol-5-yl)carbonylamino)propanoic acid;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-nitrophenyl)carboxamide;
tert-butyl-2-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)acetate;
4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino) butanoic acid;

N-(3-aminophenyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 2-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetic acid;
 5-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}pentanoic acid;
 4-(((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}methyl)benzoic acid;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridylmethyl)carboxamide;
 2-(4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}phenyl)acetic acid;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N,N-dimethylcarboxamide;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarboxamide;
 N-(3-aminoethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 N-(3-aminopropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxypropyl)carboxamide;
 N-(2H-1,2,3,4-tetrazol-5-yl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 {3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-morpholin-4-ylpropyl)carboxamide;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridylmethyl)carboxamide;
 N-(((2R)-2-hydroxycyclohexyl)methyl)(3-(4-fluorophenyl)(1H-indazole-5-yl))carboxamide;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-(1-methylimidazol-5-yl)ethyl)carboxamide;
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridylmethyl)carboxamide;
 N-(2-carbamoyl)ethyl(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 N-(3-carbamoylpropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 3-(4-methoxyphenyl)-1H-indazole-5-carboxamide;
 3-(4-hydroxyphenyl)-1H-indazole-5-carboxamide;
 3-(2-naphthyl)-1H-indazole-5-carboxamide;
 3-benzo(b)thiophen-2-yl-1H-indazole-5-carboxamide;
 3-benzo(d)furan-2-yl-1H-indazole-5-carboxamide;
 3-(3-(methylethyl)phenyl)-1H-indazole-5-carboxamide;
 3-(4-(dimethylamino)phenyl)-1H-indazole-5-carboxamide;
 3-(3-furyl)-1H-indazole-5-carboxamide;
 3-{4-(2-(dimethylamino)ethoxy)phenyl}-1H-indazole-5-carboxamide;
 3-(3,4-dimethoxyphenyl)-1H-indazole-5-carboxamide;
 3-(3-aminophenyl)-1H-indazole-5-carboxamide;
 3-(2H-benzo(d)1,3-dioxolen-5-yl)-1H-indazole-5-carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(methylethyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-(dimethylamino)ethyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(4-(dimethylamino)butyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(3-(dimethylamino)propyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methylpropyl)carboxamide;
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-methylcarboxamide;
 3-(3-(3-pyridylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-methoxyacetylaminophenyl)-1H-indazole-5-carboxamide;
 3-(3-(4-piperidylcarboxyamino)phenyl)-1H-indazole-5-carboxamide;
 (1S)-1-{N-(3-(5-carbamoyl(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;
 3-{3-(2-methoxyethyl)amino}phenyl}-1H-indazole-5-carboxamide;
 3-(3-(3-piperidylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-furylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
 3-{3-(2-(dimethylamino)acetylaminophenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-phenylacetylaminophenyl)-1H-Indazole-5-carboxamide;
 3-{3-(2-(4-methoxyphenyl)acetylaminophenyl)-1H-indazole-5-carboxamide;
 3-{3-(2-(2-methyl-1,3-thiazol-5-yl)acetylaminophenyl)-1H-indazole-5-
 carboxamide;
 3-(3-(oxolan-3-yl-carbonylamino)phenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-(3-thienyl)acetylaminophenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-thienylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
 3-(3-(2-(4-pyridyl)acetylaminophenyl)-1H-Indazole-5-carboxamide;
 3-(3-(2-(2-pyridyl)acetylaminophenyl)-1H-Indazole-5-carboxamide;
 3-{3-(2-(4-fluorophenyl)acetylaminophenyl)-1H-indazole-5-carboxamide;
 3-(3-(cyclopropylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;
 3-{3-((3-hydroxyphenyl)carbonylamino)phenyl}-1H-indazole-5-carboxamide;
 3-{3-(2-(2,4-dichlorophenyl)acetylaminophenyl)-1H-indazole-5-carboxamide;
 3-(3-{2-(4-(trifluoromethyl)phenyl)acetylaminophenyl)-1H-indazole-5-
 carboxamide;
 3-(3-{2-(4-(dimethylamino)phenyl)acetylaminophenyl)-1H-indazole-5-
 carboxamide;

3-{3-(2-(2-chloro-4-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(4-chlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(3-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-(3-(4-fluorophenyl)propanoylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(3,4-difluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-piperidylethoxy)phenyl)-1H-indazole-5-carboxamide;

N-ethyl-3-((3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino} propanamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-methoxypropyl)carboxamide;

3-{3-(N-(2-piperidylethyl)carbonyl)phenyl}-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxypropyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(oxolan-2-ylmethyl)carboxamide;

3-(2H, 3H-benzo(e)1,4-dioxin-6-yl)-1H-indazole-5-carboxamide;

3-(3-quinolyl)-1H-indazole-5-carboxamide;

3-(6-methoxy-2-naphthyl)-1H-indazole-5-carboxamide;

3-(2,3-dihydrobenzo(b)furan-5-yl)-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-oxo-3-pyrrolidinylpropyl) carboxamide;

3-((3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-methyl propanamide;

3-((3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N,N-dimethyl

propanamide;

3-((3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-(2-methoxyethyl)propanamide; or a pharmaceutically acceptable salt thereof.

109. (Previously presented) A compound of claim 12, wherein the compound is:

phenyl-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

N-(3-phenyl(1H-indazol-5-yl))-2-pyridylcarboxamide;

methyl 4-(N-(3-phenyl-1H-indazol-5-yl)carbonyl)benzoate;

4-(N-(3-phenyl-1H-indazol-5-yl)carbonyl)benzoic acid;

(2-hydroxyphenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

AUG 17 2005

N-(3-(phenyl-1H-indazole-5-yl))acetamide;
 (4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;
 (3-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl)) (2-methylphenyl)carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methoxyphenyl)carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-phenylphenyl)carboxamide;
 benzo(b)thiophen-2-yl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 methyl 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-pyridylcarboxamide;
 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
 cyclopropyl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 methyl 4-{N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoate;
 4-{N-(3-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoic acid;
 methyl 3-{N-((4-fluorophenyl)-1H-indazol-5-yl} carbamoyl}benzoate;
 3-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
 N-(3-(4-fluorophenyl)-(1H-indazol-5-yl))(4-(N-methylcarbamoyl)phenyl)carboxamide;
 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzamide;
 1-4-{N-(3-(4-methoxyphenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;
 4-(N-(3-(4-pyridyl)-1H-indazol-5-yl)carbamoyl)benzoic acid;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))benzamide;
 (3,4-bis(trifluoromethyl)phenyl)-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-furylcarboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(3,4-dichlorophenyl)carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-hydroxyphenyl)carboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4-pyridylcarboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-pyridylcarboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-thienylcarboxamide;
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))morpholin-4-yl-carboxamide;
 [N-(((2R)-2-hydroxycyclohexyl)methyl) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;] or a pharmaceutically acceptable salt thereof.

114. (Previously presented) A compound of claim 18, wherein the compound is:

3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-methyl-4H-1,2,4-triazole;
5-{3-(4-fluorophenyl)(1H-indazole-5-yl)}-3-(methylethyl)-4H-1,2,4-triazole;
1-{5-(3-(4-fluorophenyl)-1H-indazole-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;
5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-propyl-4H-1,2,4-triazole;
5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;
4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenol;
(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)dimethylamine;
{2-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;
3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)furan;
1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;
5-(3-naphthyl-1H-indazol-5-yl)-1H-1,2,4-triazole;
3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)thiophene;
5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenylamine;
3-(3-(3,4-dichlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;
3-(3-(4-methylphenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)acetamide;
5-(3-(3-chlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
2-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;
1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfonyl)benzene;
1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfinyl)benzene;
5-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;
4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenylamine;
5-{3-(4-(trifluoromethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;
(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl) (methylsulfonyl)amine;
N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;
N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;
5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

AUG 17 2005

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
 1-{5-{3-(4-fluorophenyl)1H-indazol-5-yl}-4H-1,2,4-Triazol-3-yl} ethan-1-ol;
 1-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;
 {3-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;
 {2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-yl-ethoxy)benzene;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-pyrrolidinylethoxy) benzene;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
 1-{2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethyl} pyrrolidin-2-one;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperazinylethoxy) benzene;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(3-piperdylpropoxy) benzene;
 4-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}-1-acetylpiperazine;
 2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethylamine;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-cyclohexylethoxy) benzene;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-azaperhyroepinylethoxy)benzene;
 N-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furyl caroxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-benzyl caroxamide;
 5-(3-(2-chlorophenyl)-1H-indazol-3-yl)-1H-1,2,4-triazole;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2,2-dimehtylpropyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(cyclopropylmethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridylmethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-4-methyl piperazinyl ketone;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-indan-2-ylcarboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)indanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-
 ((1S)indanyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S,2R)-2-
 hydroxyindanyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((2S,1R)-2-
 hydroxyindanyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1-methyl-1-
 phenylethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(tert-butyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)-1-
 phenylethyl)carboxamide;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-isoindolin-2-yl ketone;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2-(dimethylamino)
 ethyl)carboxamide;
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1R)indanyl benzene;
 {5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-(1,2,4)-triazol-3-ylmethyl}-dimethyl-
 amine;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxypropanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-
 (dimethylamino)acetamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)butanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopropylcarboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(6-chloro(3-
 pyridyl))carboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopentylcarboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzo(b)thiophen-2-
 carboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-furylcarboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)isoxazol-5-ylcarboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)pentanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-4-pyridylcarboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-cyclohexylacetamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-propanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-fluorophenyl)acetic acid;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2R)-2-hydroxy-2-phenylacetamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxy-2-phenylacetamide;
 (2-{3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;
 diethyl({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)amine;
 ({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)methylamine;
 ({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;
 (2R)-N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-methylbutanamide;
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
 (3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;

AUG 17 2005

(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-
 N-((*tert*-butyl)methyl)carboxamide;
 ((1R)indanyl)(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-
 3-yl))phenyl)carboxamide;
 ({3-(3-(4-methoxyphenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-
 yl)}methyl)dimethylamine;
 {(3-(3-(2H-benzo(d)1,3-dioxolen-5-yl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-
 yl)}methyl}dimethylamine;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-(2-piperidylethyl)carboxamide;
 ((5-(3-benzo(D)furan-2-yl)(1H-indazol-5-yl))(1H-1,2,4-triazol-3-
 yl))methyl)dimethylamine;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-benzamide;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-(4-fluorophenyl)carboxamide-2HCl;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-indan-2-yl-carboxamide;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-cyclopropylcarboxamide;
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-
 N-cyclobutylcarboxamide-2HCl;
 1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(2-methoxyethoxy)benzene;
 1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(3-pyridylmethoxy)benzene;
 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid;
 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid N-(4-(5-(1H-1,2,4-triazol-
 3-yl)(1H-indazol-3-yl))phenyl)-2-(3-pyridyl)acetamide;
 N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;
 N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
 N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-
 (dimethylamino)acetamide;
 (4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(methylsulfonyl)amine;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-methoxyethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-benzamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-phenethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-morpholin-4-ylethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclohexylcarboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclopentylcarboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(4-fluorophenyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-((1R,2R)-2-phenylcyclopropyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclopropylcarboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(5,6,7,8-tetrahydronaphthyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(1-benzyl(4-piperidyl))carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(1-benzylpyrrolidin-3-yl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(methylethyl)carboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclobutylcarboxamide;
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(4-pyridyl)carboxamide;
 6-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2H,3h-benzo(e)1,4-dioxin;
 6-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))-2-methoxynaphthalene;
 3-(3-(3-quinoyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;
 5-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2,3-dihydrobenzo(b)furan;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2,4-dichlorophenyl)carboxamide;

AUG 17 2005

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methoxyphenyl)carboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methylphenyl)carboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-chlorophenyl)carboxamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methylpropanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-methylbutanamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-morpholin-4-yl-acetamide;
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-methylpiperazinyl)acetamide;
 2-methoxy-6-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}naphthalene;
 N-phenyl(3-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)})phenylcarboxamide;
 6-{5-(5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl}-2H,3H-benzo(e)1,4-dioxin; or a pharmaceutically acceptable salt thereof.

115. (Previously presented) A compound of claim 19, wherein the compound is:

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
 1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-2-methoxybenzene;
 5-(3-(3-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
 2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;
 5-{3-(4-(methylethyl)phenyl)-1H-indazol-5-yl}-2H-1,2,3,4-tetrazole;
 2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)furan;
 3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenylamine;
 5-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;
 3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;
 5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;
 1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;
 1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-methylpropoxy)benzene; AUG 17 2005
 5-(3-(4-chlorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-3-methoxybenzene;
 5-(3-(4-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
 2-(5-(2H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;
 2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;
 3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;
 5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;
 5-(3-(2-phenylethyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;
 2-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;
 1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-morpholin-4-
 ylethoxy)benzene;
 N-(3-(5-2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-
 piperidylpropanamide;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;
 1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-
 ylethoxy)benzene;
 4-(5-(2H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-1,2-dimethoxybenzene;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-
 methoxypropanamide;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
 {3-(4-(5-(1H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenoxy)propyl}
 dimethylamine;
 {3-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}
 dimethylamine;
 {2-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)(2S)-2-
 hydroxypropanamide;
 N-(4-(5-(2H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;
 or a pharmaceutically acceptable salt thereof.

3-(4-fluorophenyl)-5-imidazol-2-yl-1H-indazole, or a pharmaceutically acceptable salt thereof.

117. (Previously presented) A compound, wherein the compound is:
3-phenyl-5-(phenylmethoxy)-1H-indazole;
(3-(4-fluorophenyl)(1H-indazol-5-yl))(phenylsulfonyl)amine;
3-(4-fluorophenyl)-1H-indazole-5-carboxylate;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(phenylmethoxy)carboxamide;
3-(4-fluorophenyl)-1H-indazole-5-carbohydroxamic acid;
N-((tert-butoxy)carbonylamino) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;
N-amino(3-(4-fluorophenyl)(1 H-indazol-5-yl))carboxamide;
methyl-3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylate;
3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

118-119. (Canceled)


AUG 17 2005

REMARKS

Claims 6, 10-12, 18-20, 74, 85, 89-92, 98-100, 104-109 and 114-117 are presently pending. Claims 5, 13, 22-69, 71-73, 75-84, 86-88, 93, 101, 102, 118 and 119 have been canceled without prejudice. The Advisory Action mailed February 27, 2004 indicated that the amendments set forth in the Reply to Final Office Action Under 37 C.F.R. § 1.116 filed in the United States Patent and Trademark Office on January 30, 2004 (the "January 30, 2004 Reply") were not entered. To expedite prosecution but without acquiescing in any rejection, Applicants have canceled claims 5, 13, 73, 88, 93, 103, 110, 118 and 119 which were amended in the January 30, 2004 Reply. Applicants fully incorporate the arguments set forth in the January 30, 2004 Reply, as well as all papers submitted therewith, into the present response. No new matter has been added. Applicants reserve the right to prosecute the subject matter of any canceled or amended claim or any other unclaimed subject matter in one or more continuation, divisional or continuation-in-part applications.



Applicants thank the Examiner for extending the courtesy of informal telephonic interviews on March 10, 2004 and March 12, 2004 in connection with the above-identified application.

In view of the telephonic interview of March 12, 2004, Applicants take this opportunity to clarify the phrase "3-triazolyl, optionally substituted at its 5-position" as recited in claim 18. This language refers to a moiety having the formula:



wherein C-3 of the 1,2,4-triazole moiety is bonded to the indazole core structure and C-5 of the 1,2,4-triazole moiety is bonded to hydrogen or to a substituent. The 1,2,4-triazole moiety can exist in different resonance forms which are illustrated in the examples set forth in the specification. Depending on whether or not the 1,2,4-triazole moiety is substituted or the particular resonance form drawn, the naming of the compounds (*e.g.*, 1,2,4-triazol-5-yl or 1,2,4-triazol-3-yl) can vary, as illustrated below.

AUG 17 2005



Applicants have reviewed claim 114 and believe that all compounds recited in claim 114 are those wherein R_2 is 3-triazolyl, optionally substituted at its 5-position, as recited in claim 18 from which claim 114 depends.

Applicants have also reviewed claim 115, which depends from claim 19, and believe that all compounds recited in claim 115 are those wherein R_2 is tetrazole as recited in claim 19.

Applicants have also reviewed claim 116, which depends from claim 20, and believe that the compound recited in claim 116 is that wherein R_2 is imidazole as recited in claim 20.

Accordingly, as discussed with the Examiner on March 10, 2004, Applicants believe that the presently rejected claims are not anticipated by or obvious over U.S. Publication No. 2002/0161022 A1 (now U.S. Patent No. 6,555,539) by Reich *et al.* ("Reich") and are in condition for allowance. In particular, as discussed with the Examiner, Applicants believe that the presently rejected claims are not obvious over Reich in view of the Federal Circuit's holding that the disclosure of a chemical genus does not render obvious any compound falling within the genus, particularly when the disclosure indicates a preference leading away from the claimed compounds. *In re Baird*, 16 F.3d 380, 382-383 (Fed. Cir. 1994).

Accordingly, in view of the January 30, 2004 Reply and the informal telephonic interviews on March 10, 2004 and March 12, 2004 with the Examiner, Applicants respectfully submit that the rejection of claims 18-20, 71, 72, 74, 85, 98-100, 104, 105 and 114-116 under 35 U.S.C. § 103(a) has been overcome and must be withdrawn.

Conclusion

Applicants respectfully request that the present amendments be entered and the present remarks be made of record in the file history of the present application. An early allowance of the application is earnestly requested. The Examiner is invited to call the undersigned with any questions concerning the foregoing.

Applicants believe that the only fees due are those for the Petition for Extension of Time Under 37 C.F.R. § 1.136(a) (1 month); however, in the event any additional fee(s) is required, please charge the required fee(s) to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

Date: June 9, 2004

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

222 East 41st Street

New York, New York 10017

(858) 314-1130

AUG 17 2005